ClinicalTrials.gg
CompletedNCT00083213Updated Jun 3, 2016

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

A Phase 1 interventional study of ziv-aflibercept in Cancer, sponsored by Regeneron Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2016-06-03.

Primary conditionLymphoma, Non-HodgkinRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Non-Hodgkin
Why
  1. The study's title name Lymphoma, Non-Hodgkin, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States — 137 open to participants now, 252 under way, 19 of them phase 3. Lymphoma, Non-Hodgkin · United States.

Enrollment
845th of 1,377
25 · median 35
Started
2004
with 69 others
Phase 1
528 of 1,599
47 open now
Registered
324th of 1,599
by date

Among the 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States, this one is the 845th largest by enrollment of the 1,377 interventional ones that give a count, is one of 70 that started in 2004, is one of 528 in phase 1, and was the 324th registered.

Lymphoma, Non-Hodgkin

2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

137 of the 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States are open now. Recruiting first, the newest first:

132 more — sign in →

All 137 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 242 Lymphoma, Non-Hodgkin studies recruiting now, 142 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States, or all of them as a file.
02

Study summary

RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the tumor.

PURPOSE: This phase I trial is studying the side effects and best dose of intravenous VEGF Trap in treating patients with relapsed or refractory advanced solid tumors or non-Hodgkin's lymphoma.

Read the detailed description

OBJECTIVES:

Primary

  • Determine the safety and tolerability of intravenous VEGF Trap in patients with relapsed or refractory advanced solid tumors or non-Hodgkin's lymphoma.

Secondary

  • Determine the maximum tolerated intravenous dose of this drug in these patients.
  • Determine the pharmacokinetics of this drug in these patients.
  • Determine the ability of this drug to bind circulating vascular endothelial growth factor in these patients.
  • Determine, preliminarily, the ability of this drug to alter tumor blood flow and tumor vascular permeability in these patients.
  • Determine whether antibodies to this drug develop in these patients.

OUTLINE: This is an open-label, dose-escalation, multicenter study.

Patients receive VEGF Trap IV over 1 hour on days 1 and 15 for a total of 2 doses.

Cohorts of 3-6 patients receive escalating doses of VEGF Trap until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional 6 patients are treated at that dose level.

In the absence of dose-limiting toxicity, patients with stable disease or partial or complete remission may continue to receive VEGF Trap on a separate extension protocol.

Patients are followed at weeks 1, 3, and 7 and then at 3 months.

PROJECTED ACCRUAL: A maximum of 25 patients will be accrued for this study.

03

Conditions studied

  • Cancer

Keywords

  • recurrent grade 1 follicular lymphoma
  • stage IV grade 1 follicular lymphoma
  • recurrent grade 2 follicular lymphoma
  • stage IV grade 2 follicular lymphoma
  • recurrent grade 3 follicular lymphoma
  • stage IV grade 3 follicular lymphoma
  • recurrent adult diffuse small cleaved cell lymphoma
  • stage IV adult diffuse small cleaved cell lymphoma
  • recurrent adult diffuse large cell lymphoma
  • stage IV adult diffuse large cell lymphoma
  • stage IV adult diffuse mixed cell lymphoma
  • recurrent adult diffuse mixed cell lymphoma
  • recurrent adult immunoblastic large cell lymphoma
  • stage IV adult immunoblastic large cell lymphoma
  • recurrent adult Burkitt lymphoma
  • stage IV adult Burkitt lymphoma
  • recurrent mantle cell lymphoma
  • stage IV mantle cell lymphoma
  • recurrent adult lymphoblastic lymphoma
  • stage IV adult lymphoblastic lymphoma
  • unspecified adult solid tumor, protocol specific
  • recurrent adult soft tissue sarcoma
  • recurrent adult primary liver cancer
  • advanced adult primary liver cancer
  • recurrent cervical cancer
  • stage IVA cervical cancer
  • stage IVB cervical cancer
  • fallopian tube cancer
  • ovarian sarcoma
  • recurrent ovarian epithelial cancer
  • stage IV ovarian epithelial cancer
  • recurrent endometrial carcinoma
  • stage IV endometrial carcinoma
  • recurrent uterine sarcoma
  • stage IV uterine sarcoma
  • recurrent ovarian germ cell tumor
  • stage IV ovarian germ cell tumor
  • ovarian stromal cancer
  • recurrent vaginal cancer
  • stage IVA vaginal cancer
  • stage IVB vaginal cancer
  • recurrent prostate cancer
  • stage IV prostate cancer
  • recurrent penile cancer
  • stage IV penile cancer
  • recurrent malignant testicular germ cell tumor
  • stage III malignant testicular germ cell tumor
  • recurrent bladder cancer
  • stage IV bladder cancer
  • recurrent vulvar cancer
  • stage IVB vulvar cancer
  • distal urethral cancer
  • proximal urethral cancer
  • recurrent urethral cancer
  • urethral cancer associated with invasive bladder cancer
  • primary peritoneal cavity cancer
  • recurrent marginal zone lymphoma
  • recurrent small lymphocytic lymphoma
  • stage IV small lymphocytic lymphoma
  • stage IV marginal zone lymphoma
  • extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
  • nodal marginal zone B-cell lymphoma
  • splenic marginal zone lymphoma
  • stage IV adult soft tissue sarcoma
04

In context

Lymphoma, Non-Hodgkin Reclassified

2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

This study's enrollment of 25 is below the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.

Browse Lymphoma, Non-Hodgkin studies →

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Compared within Lymphoma, Non-Hodgkin, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DISEASE CHARACTERISTICS:

  • confirmed diagnosis of one of the following:

    • Non-Hodgkin's lymphoma
    • Primary or solid tumor located, by radiography, in at least one of the following sites:

      • Liver
      • Soft tissue
      • Pelvis
      • Other site that is suitable for delayed contrast-enhanced MRI (e.g., peripheral lung field)
  • (including unresectable) disease

    • Patients with solid tumors must have failed all curative chemotherapeutic regimens
    • Patients with non-Hodgkin's lymphoma must be refractory to at least 2 standard chemotherapeutic regimens and rituximab
  • Not amenable to available conventional therapies AND no standard therapy exists
  • No prior or concurrent (brain or )
  • No primary intracranial tumor by MRI or CT scan
  • No histologically confirmed squamous cell carcinoma of the lung

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • 0-2

  • Not specified

Hematopoietic

  • WBC ≥ 3,500/mm\^3
  • ≥ 1,500/mm\^3
  • ≥ 9.0 g/dL
  • count ≥ 100,000/mm\^3
  • No severe or uncontrolled hematologic condition

Hepatic

  • ≤1.5 times (ULN)
  • and ALT ≤ 2.5 times ULN
  • PT and normal
  • INR normal
  • surface antigen negative
  • antibody negative

Renal

  • Creatinine ≤ ULN
  • Urine protein/creatinine ratio ≤ 1
  • No severe or uncontrolled renal condition

Cardiovascular

  • No acute electrocardiographic abnormalities
  • normal by echocardiogram or MUGA within the past 12 months if there was prior exposure to anthracyclines
  • No untreated or uncontrolled hypertension

    • No blood pressure > 150/100 mm Hg (despite treatment)
  • No isolated systolic hypertension (i.e., systolic blood pressure > 180 mm Hg on at least 2 determinations [on separate days] within the past 3 months)
  • No class II - IV heart disease
  • No active coronary artery disease requiring acute medical management
  • No angina requiring acute medical management
  • No congestive heart failure requiring acute medical management
  • No ventricular arrhythmia requiring acute medical management
  • No stroke or transient ischemic event within the past 6 months
  • No prior or concurrent peripheral vascular disease

    • No angiographically or ultrasonographically documented arterial or venous occlusive event
    • No symptomatic claudication
  • No symptomatic orthostatic hypotension
  • No other severe or uncontrolled cardiovascular condition

Pulmonary

  • No severe or uncontrolled pulmonary condition
  • No pulmonary embolism within the past 6 months

Immunologic

  • negative
  • No severe or uncontrolled immunologic condition
  • No active current infection requiring antibiotics
  • No prior reaction to any recombinant proteins, including VEGF Trap

Other

  • No severe or uncontrolled gastrointestinal or musculoskeletal condition
  • No psychiatric condition or adverse social circumstance that would preclude study participation
  • No other condition that would preclude study participation
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective double-barrier during and for 3 months after study treatment

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • See Disease Characteristics
  • No prior participation in a VEGF Trap, interleukin-1 Trap, or interleukin-4/13 Trap clinical trial
  • At least 3 weeks since prior immunotherapy and recovered
  • No concurrent epoetin alfa, filgrastim (G-CSF), or sargramostim (GM-CSF)

Chemotherapy

  • See Disease Characteristics
  • At least 3 weeks since prior chemotherapy and recovered

Endocrine therapy

  • No concurrent adrenal except low-dose replacement therapy
  • No concurrent systemic hormonal contraceptive agents

Radiotherapy

  • At least 3 weeks since prior radiotherapy and recovered

Surgery

  • At least 3 weeks since prior major or laparoscopic surgery and recovered
  • More than 6 months since prior surgical procedure for correction or prophylaxis of peripheral vascular insufficiency or cerebral ischemic events

Other

  • More than 30 days since prior drugs
  • No concurrent anticoagulant or antiplatelet drugs (e.g., warfarin, heparin, or aspirin) other than low-dose (1 mg) warfarin for maintaining patency of venous access devices
  • No concurrent non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 (COX-2) inhibitors
  • No other concurrent anticancer investigational agents
  • No other concurrent anticancer therapy
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Interventions

07

Study locations

1 site
  • Memorial Sloan - Kettering Cancer Center
    New York, New York 10021, United States
08

References and documents

Publications

  • Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, Buzenet G, Koehler E, Sosman JA, Schwartz LH, Gultekin DH, Koutcher JA, Donnelly EF, Andal R, Dancy I, Spriggs DR, Tew WP. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol. 2010 Jan 10;28(2):207-14. doi: 10.1200/JCO.2009.22.9237. Epub 2009 Nov 30. PubMed 19949018 ↗
  • Wang-Gillam A, Tew WP, Rothenberg ML, Dupont J, Cooper W, Sternas L, Buzenet G, Sosman JA, Spriggs DR, Lockhart AC. A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors. Invest New Drugs. 2012 Oct;30(5):1958-61. doi: 10.1007/s10637-011-9753-y. Epub 2011 Oct 15. PubMed 22002018 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2004 and a primary completion of May 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2004
First posted
May 19, 2004
Start
Jan 2004
Primary completionActual
May 2008
Last update
Jun 3, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00083213
Responsible party
Sponsor
First posted
May 19, 2004
Start date
Jan 2004
Primary completion
May 2008
Last update
Jun 3, 2016

Study contacts

William P. Tew, MD
principal investigator · Memorial Sloan Kettering Cancer Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion